Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 8/22/17 → 3/21/22 |
Financiación
- Rebiotix Inc: 22.046,00 US$
17-ID-207: A Phase 3 Prospective, Randomized, Double-Blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
- Greenberg, Richard (PI)